Street Calls of the Week
MONTREAL - CB Biotechnology, LLC, an affiliate of Future Pak, LLC, has completed its acquisition of Theratechnologies Inc. (TSX:TH) (NASDAQ:THTX), a specialty biopharmaceutical company with $84.38 million in trailing twelve-month revenue and an impressive 77.72% gross profit margin, the company announced Thursday.
Under the arrangement, CB Biotechnology acquired all issued and outstanding common shares of Theratechnologies for US$3.01 per share in cash, plus one contingent value right (CVR) per share that could provide additional payments of up to US$1.19 if certain company milestones are achieved.
Based on an independent valuation, the fair market value of each CVR has been determined to be US$0.80 as of Wednesday.
The consideration for the shares has been remitted to Computershare Investor Services Inc. as depositary and will be paid to former shareholders as soon as reasonably practicable.
Following the transaction completion, Theratechnologies shares, which recently traded near their 52-week high of $3.39, are expected to be delisted from the Toronto Stock Exchange on or about Friday and from the Nasdaq Capital Market on Thursday. The company, with a market capitalization of $154.72 million, will apply to cease being a reporting issuer under Canadian securities laws and will deregister its shares under the U.S. Securities Exchange Act of 1934. For comprehensive analysis of similar biotech opportunities, investors can access detailed Pro Research Reports on over 1,400 stocks through InvestingPro.
Prior to the arrangement, CB Biotechnology and its affiliates did not own any shares of Theratechnologies.
Theratechnologies is a specialty biopharmaceutical company focused on commercializing innovative therapies, while Future Pak is a privately held contract manufacturer, packager and distributor of pharmaceutical and nutraceutical products headquartered in Wixom, Michigan.
This article is based on information provided in a company press release.
In other recent news, Theratechnologies Inc. has received final approval from the Superior Court of Quebec for its acquisition by CB Biotechnology, LLC, an affiliate of Future Pak, LLC. This court approval follows a shareholder vote, which took place on September 12, 2025, endorsing the plan of arrangement. The acquisition is expected to close around September 25, 2025, pending the satisfaction of remaining conditions. Under this agreement, shareholders will receive $3.01 per share in cash and a contingent value right (CVR) potentially worth up to an additional $1.19 per share if certain milestones are met.
Additionally, Jones Trading has downgraded Theratechnologies from a Buy to a Hold rating following the acquisition agreement. Despite the downgrade, Jones Trading noted that the full $1.19 CVR is likely to be realized within three years if the acquisition with Future Pak is completed. This acquisition deal values Theratechnologies at a total potential of $4.20 per share, combining the cash offer and the CVR. These developments mark significant steps in Theratechnologies’ ongoing acquisition process.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.